{"id":"NCT03939637","sponsor":"Baylor College of Medicine","briefTitle":"Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children","officialTitle":"A Phase III Study of Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia in Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-02","primaryCompletion":"2024-04-17","completion":"2025-02-26","firstPosted":"2019-05-07","resultsPosted":"2025-07-29","lastUpdate":"2025-07-29"},"enrollment":122,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Immune Thrombocytopenia"],"interventions":[{"type":"DRUG","name":"Eltrombopag","otherNames":[]},{"type":"DRUG","name":"Steroids","otherNames":[]},{"type":"DRUG","name":"IVIG","otherNames":[]},{"type":"DRUG","name":"Rho(D) Immune Globulin","otherNames":[]}],"arms":[{"label":"Eltrombopag","type":"EXPERIMENTAL"},{"label":"Standard first-line therapy","type":"ACTIVE_COMPARATOR"}],"summary":"This is an investigator initiated, multicenter, open label, randomized phase 3 study for subjects with newly diagnosed ITP from ages 1 to less than 18 years old.","primaryOutcome":{"measure":"Proportion of Patients With a Platelet Response","timeFrame":"12 weeks","effectByArm":[{"arm":"Experimental: Eltrombopag","deltaMin":52,"sd":null},{"arm":"Comparator: Standard Therapy","deltaMin":14,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":24},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":["34452956"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":78},"commonTop":["Headache","Anemia","Epistaxis","Fall","Suicidal ideation"]}}